

Synapse

3rd Edition

Hypothyroidism & Pregnancy



Dr Prof (Col) Pankaj Talwar
VSM, MD, PhD.
President



Dr (Prof) Shweta Mittal Gupta
MD, DNB, FNB, MNAMS
Secretary General



Dr Parul Garg
MBBS(LHMC), MD(MAMC), FNB
(Reproductive Medicine,SGRH), FICOG,
FICMCH HOD of reproductive medicine
Artemis Hospital, Gurgaon



Dr Rupali Bassi Goyal
Editor



Dr Nymphaea Walecha
Joint Editor



Dr Garima Kapur
Editorial Board



Dr Niti Vijay
Editorial Board

The thyroid gland controls rate of metabolic processes throughout the body via the production of two hormones triiodothyronine (T3) and thyroxine (T4). As the function of the thyroid gland is under the control of the hypothalamo-pituitary axis, changes in thyroid function can impact greatly on reproductive function before, during and after conception. Thyroid disease is classically divided into hyperthyroidism and hypothyroidism, and the causes of thyroid disease are numerous¹ (Table 1).¹

Primary Hypothyroidism	Secondary Hypothyroidism	Tertiary Hypothyroidism
Autoimmune Diseases: Atrophic Thyroiditis Hashimotos Thyroiditis	Pituitary Failure Pituitary Tumor	Hypothalamic Failure
Iatrogenic: Radioiodine therapy Thyroidectomy Antithyroid drugs		
Transient: Subacute Thyroiditis Postpartum Thyroiditis		
Iodine Deficiency		

Normal pregnancy is associated with an increase in renal iodine excretion, an increase in thyroxine binding proteins, an increase in thyroid hormone production and thyroid stimulatory effects of hCG, human Chorionic Gonadotropin (reduction in serum TSH, Thyroid Stimulating Hormone). Following conception, circulating thyroxine binding globulin (TBG) and total T4 concentrations increase by 7 week of gestation and reach a peak by 16 week of gestation and remain high until delivery.

Hypothyroidism in pregnancy is a common condition with overt disease affecting approximately 0.5% of women, and subclinical disease approximately 2.5%. When iodine nutrition is adequate, **the most frequent cause of hypothyroidism is autoimmune thyroid disease (Hashimoto's thyroiditis)**. The thyroid autoantibodies can be detected in approximately 30%–60% of pregnant women with an elevated TSH concentration.²

Both overt and subclinical hypothyroidism are associated with an increased risk of adverse obstetric and neonatal outcomes (Table 2).¹

Table 2: Complications of Hypothyroidism in Pregnancy¹

Maternal	Neonatal
Anemia	Fetal Distress in labor
Post Partum Haemorrhage	Prematurity/Low birth weight
Cardiac Dysfunction	Congenital Malformations
Preeclampsia	Perinatal Death
Placental abruption	Still Birth/Neurodevelopmental delay

Screening

The universal screening for abnormal TSH concentrations in early pregnancy is not recommended. At present a high-risk screening approach is currently adopted, therefore women at high risk (Table 3) should be screened.²

Table 3: Risk Factors for Thyroid Dysfunction²

Family/ Personal history of thyroid dysfunction/thyroid surgery
Goitre
Positive thyroid auto antibodies (anti TPO)
Diabetes type 1/Other autoimmune diseases
Clinical signs and symptoms of hypothyroidism

History of miscarriage/Preterm delivery
History of subfertility
History of therapeutic head and neck irradiation
Age \geq 30years/Morbid obesity (BMI \geq 40Kg/m ²)
Previous treatment with Amiodarone/Lithium
Recent exposure to iodinated radiological contrast agent
Residing in an area of known moderate or severe iodine insufficiency

Anti TPO: Thyroid Peroxidase antibodies

Diagnosis

The hypothyroidism during pregnancy is diagnosed by measuring serum TSH and serum T4.

Primary overt maternal hypothyroidism is defined as the presence of an elevated serum TSH and a decreased serum FT4 (Free Thyroxine) concentration during gestation, with both concentrations outside the (trimester-specific) reference ranges (Table 4)²

Subclinical hypothyroidism is defined as presence of an elevated serum TSH and normal serum FT4 concentration during gestation.

Table 4: Trimester Specific TSH Reference Ranges²


Trimester	TSH reference range
First (7-12 weeks)	The lower reference range of TSH can be reduced by approximately 0.4 mU/L, while the upper reference range is reduced by approximately 0.5mU/L (corresponds to 4mU/L).
Second and Third Trimesters	Nonpregnant Range (0.5mU/L to 4.5-5mU/L)

Treatment (Figure 1)²

The oral Levothyroxine (LT4) is drug of choice for treatment of hypothyroidism in pregnancy.

The dose of LT4 is increased by 20%-30% in hypothyroid patients receiving LT4 treatment with a suspected or confirmed pregnancy (e.g., positive home pregnancy test).²

Figure 1: Testing and Treatment of Hypothyroidism in Pregnancy, ULRR (Upper Limit of the Reference Range)²



To summarize, If TPOAb positive consider treatment if serum TSH is more than 2.5mU/L and if TPOAb negative consider treatment if TSH is more than ULRR.

Monitoring During Pregnancy:

Women with overt and subclinical hypothyroidism (treated or untreated) or those at risk for hypothyroidism {e.g. patients who are euthyroid but TPOAb (Thyroid Peroxidase antibody or TgAb Thyroglobulin antibodies) positive} should be monitored with a serum TSH measurement **approximately every 4 weeks until midgestation and at least once near 30 weeks gestation.**²

Postpartum:

Following delivery, LT4 should be reduced to the patient's preconception dose. Additional thyroid function testing should be performed at approximately 6 weeks post partum.²

Hypothyroidism and Infertility

Hypothyroidism affects the pulsatile release of gonadotrophin-releasing hormone, which is required for cyclical release of follicle-stimulating hormone and luteinising hormone and subsequent ovulation. Hypothyroidism in childhood and adolescence is associated with a delay in reaching sexual maturity and in adulthood is associated with menstrual disturbances (like oligomenorrhoea, menorrhagia and amenorrhoea). Hypothyroidism also alter the feedback to the pituitary by changing estrogen metabolism and circulating levels of sex hormone-binding globulin.¹

Evaluation of serum TSH concentration is recommended for all women seeking care for infertility. LT4 treatment is recommended for infertile women with overt hypothyroidism who desire pregnancy.²

The prevalence of thyroid autoimmunity is higher among infertile patients, especially when infertility is caused by endometriosis or ovulatory dysfunction. There is fair evidence that thyroid autoimmunity is associated with infertility. LT4 may improve pregnancy outcomes in female with positive thyroid antibodies especially if serum TSH is > 2.5 mIU/L.³

The overt hypothyroidism affects the semen parameters as well as sexual behavior. The treatment with LT4 has significant improvement in semen parameters and sexual behavior. The subclinical hypothyroidism does not affect the semen parameters.⁴

Hypothyroidism and Recurrent Miscarriage⁵

Women with recurrent miscarriage should be offered thyroid function tests and assessment for thyroid peroxidase (TPO) antibodies.

Thyroxine supplementation is not routinely recommended for euthyroid women with TPO who have a history of miscarriage.

References:

1. Jefferys A, Vanderpump M, Yasmin E. Thyroid dysfunction and reproductive health. *The Obstetrician & Gynaecologist* 2015;17:39–45.
2. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid* 2017;27(3):315-390.
3. Practice committee of the American Society for Reproductive Medicine. Subclinical hypothyroidism in the infertile female population: a guideline. *Fertil steril* 2015;104(3):545-553.
4. K Anand, S Skand, D Bodhana. Thyroid and Female reproduction. *Indian J Endocrinol Metab* 2014;18(1):23-31.
5. Regan L, Rai R, Saravelos S, Tin Chiu Li. Recurrent Miscarriage Green-top Guideline No. 17. *BJOG*, 2023;130:12.

IFS Central Activities

INDIAN FERTILITY SOCIETY



Free access to

IFS Genius Junction Quiz

Patient Empowerment Program (PEP)

Intelligence Empowerment Program (IEP)

Young Empowerment Program (YEP)

Counsellor Empowerment Program (CEP)

Nurses Empowerment Program (NEP)

Self Empowerment Program (SEP)

Why
Become
An
IFS Member?

Scan QR code



CALL NOW!

9899308083



Become a
Member in
3 Min



Notification
in
4 Min



Download
E Certificate &
Membership Number in
7 Min



indianfertilitysocietydelhi@gmail.com





INDIAN FERTILITY SOCIETY



How to Become an IFS Member

Dr. Prof (Col) Pankaj Talwar, VSM
President, IFS

Dr. (Prof) Shweta Mittal Gupta
Secretary General, IFS



For any Information, Contact

+91 9899308083

indianfertilitysocietydelhi@gmail.com



INDIAN FERTILITY SOCIETY

Has successfully launched (SEP)

Self Empowerment Program



Dr. Col. (Prof) Pankaj Talwar, VSM

President, IFS



Dr. (Prof) Shweta Mittal Gupta

Secretary General, IFS

IFS SECRETARIAT

302, 3rd Floor, Kailash Building,
26, Kasturba Gandhi Marg, C.P.
New Delhi - 110001

+91-9899308083 (Ms Farah Khan)

www.indianfertilitysociety.org

indianfertilitysocietydelhi@gmail.com



INDIAN FERTILITY SOCIETY has successfully launched Genius Junction Quiz on Kahoot

Join us for monthly Quiz



Dr. Col. (Prof) Pankaj Talwar, VSM
President, IFS



Dr. (Prof) Shweta Mittal Gupta
Secretary General, IFS

IFS SECRETARIAT

302, 3rd Floor, Kailash Building,
26, Kasturba Gandhi Marg, C.P.
New Delhi - 110001

+91-9899308083 (Ms Farah Khan)

www.indianfertilitysociety.org

indianfertilitysocietydelhi@gmail.com



INDIAN FERTILITY SOCIETY has successfully launched YEP

Youth Empowerment Program (YEP)



Dr. Col. (Prof) Pankaj Talwar, VSM

President, IFS



Dr. (Prof) Shweta Mittal Gupta

Secretary General, IFS

IFS SECRETARIAT

📍 302, 3rd Floor, Kailash Building,
26, Kasturba Gandhi Marg, C.P.
New Delhi - 110001

☎ +91-9899308083 (Ms Farah Khan)

🌐 www.indianfertilitysociety.org

✉ indianfertilitysocietydelhi@gmail.com



INDIAN FERTILITY SOCIETY Has successfully launched (CEP)

Counsellor Empowerment Program



Dr. Col. (Prof) Pankaj Talwar, VSM
President, IFS



Dr. (Prof) Shweta Mittal Gupta
Secretary General, IFS

IFS SECRETARIAT

302, 3rd Floor, Kailash Building,
26, Kasturba Gandhi Marg, C.P.
New Delhi - 110001

+91-9899308083 (Ms Farah Khan)

www.indianfertilitysociety.org

indianfertilitysocietydelhi@gmail.com



INDIAN FERTILITY SOCIETY **has successfully launched (NEP)**

NURSES EMPOWERMENT PROGRAM

"NIGHTINGALE"

PROGRAM BY THE FERTILITY NURSES, FOR THE FERTILITY NURSES



Dr. Col. (Prof) Pankaj Talwar, VSM
President, IFS



Dr. (Prof) Shweta Mittal Gupta
Secretary General, IFS

IFS SECRETARIAT

302, 3rd Floor, Kailash Building,
26, Kasturba Gandhi Marg, C.P.
New Delhi - 110001
+91-9899308083 (Ms Farah Khan)
www.indianfertilitysociety.org
indianfertilitysocietydelhi@gmail.com



INDIAN FERTILITY SOCIETY has successfully launched iEP

INTELLIGENCE EMPOWERMENT PROGRAM (iEP)

SURF THE AI WAVE WITH IFS



Dr. Col. (Prof) Pankaj Talwar, VSM
President, IFS



Dr. (Prof) Shweta Mittal Gupta
Secretary General, IFS

IFS SECRETARIAT

📍 302, 3rd Floor, Kailash Building,
26, Kasturba Gandhi Marg, C.P.
New Delhi - 110001

☎ +91-9899308083 (Ms Farah Khan)

🌐 www.indianfertilitysociety.org

✉ indianfertilitysocietydelhi@gmail.com

In association with



INDIAN FERTILITY SOCIETY HAS SUCCESSFULLY LAUNCHED ITS

Academic Partnership



Project Sanjivni

'Patient Empowerment Program' (PEP)

Breast Cancer, Fertility Myth, Chronic Cancer Awareness, PCOS, Menstruation Hygiene

National Advisor



Dr Gouri Devi
Delhi

Convenor



Dr Prof (Col) Pankaj Talwar VSM
President, IFS

National Coordinator



Dr Sarabjeet Singh
Punjab

Co-Convenor



Dr (Prof) Shweta Mittal Gupta
General Secretary, IFS



INDIAN FERTILITY SOCIETY

Flat No. 302, 3rd Floor, Kailash Building 26, KG Marg, Connaught Place, New Delhi 110001

Contact: +91 9899308083 (Miss Farha Khan), +91 91367 89307 (Mr. Santosh Kumar)

www.indianfertilitysociety.org | indianfertilitysocietydelhi@gmail.com

www.fertivision2024.in



20th Annual Conference of Indian Fertility Society

6th, 7th & 8th December 2024 | Mahatma Mandir Convention & Exhibition Centre,
The Leela Gandhinagar, Gujarat India

"Tailoring, Transformation & Preservation in ART"



**DON'T MISS THE
LAST OPPORTUNITY**

**REGISTER NOW AND SAVE WITH
EARLY BIRD RATES BEFORE
THEY FLY AWAY!"**

EXTENDED TILL: 2ND OCTOBER

Scan me for more
information



Scan me for
Online Registration



FOLLOW US:

- indianfertilitysociety
- indianfertilitysociety
- indianfertilitysociety



Dr. Prof. (Col) Pankaj Talwar, VSM
President, IFS
Organizing Chair



Dr. (Prof) Shweta Mittal Gupta
Secretary General, IFS
Organizing Secretary



Dr. (Prof.) Neena Malhotra
President Elect, IFS
Scientific Committee Chair



Dr. Jayesh Amin
National Advisor, IFS
Organizing Chairperson, LOC

Conference Secretariat: Flat No. 302, 3rd Floor, Kailash Building, 26, KG Marg, Connaught Place, New Delhi 110001

Email: contact@fertivision2024.in | Contact: +91 9899308083, 9136789307

Email: indianfertilitysocietydelhi@gmail.com | Web.: www.fertivision2024.in